Inhalation Sciences Sweden AB ("ISAB" eller ''Bolaget'') offentliggör idag slutligt utfall i Bolagets företrädesemission av aktier och teckn...
Stockholm, 2 juni 2025 – Inhalation Sciences (ISAB) genomförde den 28 maj 2025 ett webbinarium där bolaget presenterade data från den framgå...
Stockholm, 30 maj 2025 – Inhalation Sciences Sweden AB (”ISAB” eller ”Bolaget”) meddelar att Bolagets tillträdande försäljningschef (Chief C...
Idag, den 28 maj 2025, är sista dag för handel med uniträtter i Inhalation Sciences Sweden AB (publ) ("ISAB" eller "Bolaget") företrädesemis...
Inhalation Sciences AB meddelar att bolagets årsredovisning för 2024 nu finns tillgänglig på bolagets hemsida.
Inhalation Sciences AB announces that its Annual Report for 2024 is now available on the company's website.
Stockholm, 27 maj 2025 – Inhalation Sciences Sweden AB (ISAB) har rekryterat Ulf Wedenberg som ny Chief Commercial Officer (CCO).
Stockholm, May 27, 2025 - Inhalation Sciences Sweden AB (ISAB) has recruited Ulf Wedenberg as its new Chief Commercial Officer (CCO).
Stockholm, 26 maj 2025 – Inhalation Sciences ("ISAB" eller "Bolaget") föreslagna styrelseledamot Niklas Lindecrantz har lämnat ett tecknings...
Aktieägarna i Inhalation Sciences Sweden AB (publ), org.
Inhalation Sciences Sweden AB (ISAB) genomförde den 22 maj ett webbinarium där bolaget presenterade viktiga framsteg inom affärsutveckling, ...
Stockholm, May 22, 2025 - Inhalation Sciences AB (ISAB) today announces that the company has entered into a Master Service Agreement (MSA) w...
Stockholm, 22 maj, 2025 - Inhalation Sciences AB (ISAB) meddelar idag att bolaget har ingått ett Master Service Agreement (MSA) med det USA-...
Idag, den 19 maj 2025, inleds teckningsperioden i Inhalation Sciences Sweden AB (publ) ("ISAB" eller "Bolaget") företrädesemission av aktier...
Stockholm, Sverige, 16 maj 2025 - Inhalation Sciences AB meddelar att bolagets delårsrapport för det första kvartalet 2025 nu finns tillgäng...
Inhalation Sciences Sweden AB (publ) ("ISAB" eller "Bolaget") har upprättat ett förenklat informationsdokument (”Informationsdokumentet”) oc...
Inhalation Sciences Sweden AB (publ) ("Bolaget") har beslutat att tidigarelägga publicering av delårsrapporten för perioden januari – mars 2...
Inhalation Sciences Sweden AB (publ) ("Bolaget") avhöll idag, den 8 maj 2025, en extra bolagsstämma.
Stockholm, 8 maj 2025 – Inhalation Sciences AB (ISAB) meddelar idag att bolaget mottagit två nya ordrar till ett sammanlagt värde av 27 400 ...
Stockholm, May 8, 2025 - Inhalation Sciences AB (ISAB) today announces that the company has received two new orders for a total value of EUR...
Inhalation Sciences AB (ISAB) bjuder härmed in till en digital investerarpresentation som hålls tisdagen den 22 maj klockan 10:00.
Stockholm, Sweden - April 24, 2025 - Inhalation Sciences AB (ISAB) has completed the FDA-funded study[1] of DissolvIt® (ISAB's proprietary u...
Stockholm, Sverige – 2025-04-24 - Inhalation Sciences AB (ISAB) har slutfört den FDA-finansierade studien[1] av DissolvIt® (ISAB:s egenutvec...
Stockholm, Sweden – April 15, 2025 – Inhalation Sciences AB (ISAB) has received a purchase order from a recurring global customer.
Stockholm, Sverige - 2025-04-15 – Inhalation Sciences AB (ISAB) har erhållit en inköpsorder från en återkommande global kund.
Styrelsen i Inhalation Sciences Sweden AB (publ) ("ISAB" eller "Bolaget") har idag fattat beslut om att föreslå att en extra bolagsstämma be...
Stockholm, Sweden – March 3, 2025 – Inhalation Sciences AB (ISAB), a leader in inhalation research and drug development, welcomes the U.
(Stockholm, Sverige, 28 februari 2025) Inhalation Sciences AB meddelar att bolagets delårsrapport för det fjärde kvartalet 2024 nu finns til...
(Stockholm, Sweden, 28 February 2025) Inhalation Sciences AB announces that its Q4 / Year-End Report for 2024 is now available on the compan...
(Stockholm, Sweden, 13 January 2025) Inhalation Sciences (ISAB) announces its plans to launch the company’s XposeALI[®] in vitro exposure mo...
(Stockholm, Sweden, 10 January 2025) Inhalation Sciences AB (ISAB) has received an order worth SEK 212,000 from a returning client, a global...
(Stockholm, Sweden, 9 January 2025) Inhalation Sciences Sweden AB (ISAB) is proud to announce the submission of the project report and summa...
(Stockholm, Sweden, 17 December 2024) Inhalation Sciences AB (publ), a world-leading research and development company in the field of inhala...
(Stockholm, Sweden, 20 November, 2024) Inhalation Sciences AB announces that its Q3 Report for 2024 is now available on the company's websit...
(Stockholm, Sverige, 20 november 2024) Inhalation Sciences AB meddelar att bolagets delårsrapport för det tredje kvartalet 2024 nu finns til...
(Stockholm, 16 October 2024) Inhalation Sciences Sweden AB (ISAB) today releases the latest update on progress in its FDA BAA (Broad Agency ...
A new publication demonstrates how XposeALI[®], Inhalation Sciences’ in vitro cell-based exposure module, successfully predicted the toxicit...
Inhalation Sciences Sweden AB (publ) (”Bolaget”) avhöll den 4 september 2024 extra bolagsstämma.
(Stockholm, Sweden, 28 August 2024) Inhalation Sciences AB announces that its Q2 Report for 2024 is now available on the company’s website.
(Stockholm, Sverige, 28 augusti 2024) Inhalation Sciences AB meddelar att bolagets delårsrapport för andra kvartalet 2024 finns nu tillgängl...
(Stockholm, 15 August 2024) Inhalation Sciences AB (ISAB) has received a surge of new orders, primarily for its Inhalation Research Services...
Inhalation Sciences Sweden AB’s (publ) (“Inhalation Sciences” or the “Company”) Nomination Committee proposes that Ulf Ericsson be elected a...
(Stockholm, 13 June 2024) Inhalation Sciences AB (ISAB) has received its first order for a preclinical dissolution study using its high-prec...
Inhalation Sciences CEO Manoush Masarrat discusses the company’s recent Q1 Report, and takes investors’ questions, in the first of a new reg...
(Stockholm, Sweden, 28 May 2024) Inhalation Sciences AB announces that its Q1 Report for 2024 is now available on the company’s website.
(Stockholm, Sverige, 28 maj 2024) Inhalation Sciences AB meddelar att bolagets delårsrapport för första kvartalet 2024 finns nu tillgänglig ...
On 20 May Inhalation Sciences AB CSO Per Gerde presented the company’s predictive tools for developing and assessing generic inhaled pharmac...
Inhalation Sciences AB (ISAB) has received a purchase order worth 60,000 EURO (almost 700,000 SEK) from a returning customer – one of the wo...
Inhalation Sciences Sweden AB (publ) (”Bolaget”) avhöll den 14 maj 2024 årsstämma i Huddinge.
Inhalation Sciences AB announces that its Annual Report for 2023 is now available on the company’s website.
Inhalation Sciences AB meddelar att bolagets årsredovisning för 2023 nu finns tillgänglig på bolagets hemsida.
Inhalation Sciences Sweden AB (ISAB) has been invited to provide a public comments presentation at the FDA’s public workshop GDUFA (Generic ...
I ISAB’s bokslutskommuniké för 2023 publicerad den 28e februari 2024, har intäkten från Aprinha projektet redovisats som nettoomsättning.
(Stockholm, 11 March 2024) Positive results from Inhalation Sciences’ first-in-human clinical study of its aerosol generating system Precise...
(Stockholm, Sweden, 28 February 2024) Inhalation Sciences AB announces that its Q4 / Year End Report for 2023 is now available on the compan...
(Stockholm, Sverige, 29 februari 2024) Inhalation Sciences AB meddelar att bolagets delårsrapport för fjärde kvartalet 2023 nu finns tillgän...
Inhalation Sciences AB (ISAB) has signed a new partnership with fellow European inhalation development service provider Actarmo Medical GmbH...
(Stockholm, Sweden, 29 December,2023) Inhalation Sciences AB (ISAB) has secured a product service contract with a worth of 47,000 Euro on it...
(Stockholm, Sweden, 13 December 2023) Interest and interaction was high on December 11 at ISAB’s latest industry webinar, ‘Inhaled Biologics...
(Stockholm, Sverige, 22 november 2023) Inhalation Sciences AB meddelar att bolagets delårsrapport för tredje kvartalet 2023 nu finns tillgän...
(Stockholm, Sweden, 29 August,2023) Inhalation Sciences AB announces that its Q3 Report for 2023 is now available on the company’s website.
Inhalation Sciences AB (ISAB) has received a new order worth 100 kEuro (1.
(Stockholm, Sweden, 13 November,2023) Inhalation Sciences AB has received a new purchase order worth 276,450 Euro from a returning customer,...
(Stockholm, Sweden, 8 November,2023) Inhalation Sciences AB has signed a new order valued at 54,700 Euro with a customer in Europe developin...
Join Inhalation Sciences AB (ISAB) CEO Manoush Masarrat for a 2-minute company pitch and 20-minute analyst Q&A at the livestreamed Redeye Li...
(Stockholm, October 18, 2023) Innovative Swedish MedTech company Inhalation Sciences Sweden AB (ISAB) has strengthened its IP portfolio in t...
Inhalation Sciences AB (ISAB) has been awarded a new order from a returning customer for an Inhalation Research Services (IRS) project.
Inhalation Sciences AB (ISAB) has signed a collaboration agreement with a leading Indian multinational pharma company with a powerful respir...
(Stockholm, Sweden, 29 August,2023) Inhalation Sciences AB announces that its Q2 Report for 2023 is now available on the company’s website.
(Stockholm, Sverige, 29 augusti 2023) Inhalation Sciences AB meddelar att bolagets delårsrapport för andra kvartalet 2023 nu finns tillgängl...
(Stockholm, Sweden, 23 August 2023) Inhalation Sciences AB will repay a 1.
Inhalation Sciences Sweden AB:s (publ) (”Inhalation Sciences” eller “Bolaget”) styrelseledamot Mårten Winge har idag meddelat sin avsikt att...
Företrädesemissionen i Inhalation Sciences Sweden AB (publ) (”ISAB” eller ”Bolaget”) som avslutades den 9 maj 2023 har slutregistrerats.
The rights issue in Inhalation Sciences Sweden AB (publ) ("ISAB" or the "Company") which ended on May 9, 2023 has been finally registered.
Inhalation Sciences AB (ISAB) has received a new Purchase Order worth 94,000 USD, or just over 1 million SEK, from a distributor in Asia, th...
Inhalation Sciences AB (ISAB) has received a Purchase Order, worth 125.
Inhalation Sciences AB (ISAB) has received a new order for an Inhalation Research Services (IRS) project using its predictive preclinical te...
The rights issue in Inhalation Sciences Sweden AB (publ) (“ISAB” or the ”Company”) has been partially registered with the Swedish Companies ...
Företrädesemissionen i Inhalation Sciences Sweden AB (publ) (”ISAB” eller ”Bolaget”) har delregistrerats vid Bolagsverket och betalda teckna...
(Stockholm, Sweden, 31 May 2023) Inhalation Sciences AB announces that its Q1 Report for 2023 is now available on the company’s website.
(Stockholm, Sverige, 31 maj 2023) Inhalation Sciences AB meddelar att bolagets delårsrapport för första kvartalet 2023 nu finns tillgänglig ...
(Stockholm, 25 May, 2023) Inhalation Sciences (ISAB) has been awarded 125,000 EURO for its role in the research project ‘New Inhalation Form...
Inhalation Sciences AB (ISAB) has received a new order worth 53,000 Euro from a regular client – a large global player in the field of inhal...
Inhalation Sciences Sweden AB (publ) (“ISAB” or the ”Company”) today announces the outcome of the rights issue of shares that the Company an...
Inhalation Sciences Sweden AB (publ) (“ISAB” eller ”Bolaget”) offentliggör idag utfallet av den företrädesemission av aktier som Bolaget off...
Inhalation Sciences Sweden AB (publ) (”Bolaget”) avhöll den 12 maj 2023 årsstämma i Huddinge.
Today on May 9, 2023, is the last day for participation in Inhalation Sciences Sweden AB (publ)’s ("ISAB" or the "Company") rights issue of ...
Idag, den 9 maj är sista dag för deltagande i Inhalation Sciences Sweden AB (publ):s (”ISAB” eller ”Bolaget”) företrädesemission av aktier (...
(Stockholm, 05 May 2023) Following its communication on April 18, 2023, regarding completion of the required administrative routines necessa...
(Stockholm, Sweden, 4 May 2023) Almost 200 specialists registered for ISAB’s latest experts’ webinar, now available to view online on ISAB’s...
2023 has started in line with our expectations and we continue to see a steady inflow of inquiries from various biopharma customers and good...
Today on April 24, 2023, the subscription period begins in Inhalation Sciences Sweden AB (publ)’s ("ISAB" or the "Company") rights issue of ...
Idag, den 24 april 2023, inleds teckningsperioden för Inhalation Sciences Sweden AB (publ):s (”ISAB” eller ”Bolaget”) företrädesemission av ...
Inhalation Sciences Sweden AB (publ) (“ISAB” or the “Company”) today publishes the information memorandum prepared in connection with the Co...
Inhalation Sciences Sweden AB (publ) (”ISAB” eller ”Bolaget”) offentliggör idag det informationsmemorandum som upprättats med anledning av B...
(Stockholm, Sweden, 19 April 2023) Following its highly successful webinar on DissolvIt dissolution studies on March 30[th] – 300 people reg...
(Stockholm, 18 April 2023) Inhalation Sciences Sweden AB (ISAB) has completed all the required administrative routines necessary to proceed ...
